Regional Chemotherapy Is a Valuable Second-Line Approach in Metastatic Esophageal Cancer after Failure to First-Line Palliative Treatment
Background: Therapeutic options in metastatic esophageal cancer (EC) are limited with unsatisfactory results. We evaluated the efficacy of regional chemotherapy (RegCTx) approach in diffuse metastatic EC using arterial infusion (AI), upper abdominal perfusion (UAP) and isolated-thoracic perfusion (I...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/29/7/386 |
| _version_ | 1827597537993818112 |
|---|---|
| author | Yogesh Vashist Kornelia Aigner Miriam Dam Sabine Gailhofer Karl R. Aigner |
| author_facet | Yogesh Vashist Kornelia Aigner Miriam Dam Sabine Gailhofer Karl R. Aigner |
| author_sort | Yogesh Vashist |
| collection | DOAJ |
| description | Background: Therapeutic options in metastatic esophageal cancer (EC) are limited with unsatisfactory results. We evaluated the efficacy of regional chemotherapy (RegCTx) approach in diffuse metastatic EC using arterial infusion (AI), upper abdominal perfusion (UAP) and isolated-thoracic perfusion (ITP) in 14 patients (N = 8 adenocarcinoma (AC) and N = 6 squamous cell carcinoma (SQCC)) after failure to first-line palliative treatment. Methods: All patients had previously failed first-line palliative treatment attempt with systemic chemotherapy (sCTx). In total 51 RegCTx cycles (12 AI, 3 UAP and 36 ITP) were applied using cisplatin, Adriamycin and Mitomycin C. The outcome was evaluated using RECIST criteria with MediasStat 28.5.14 and SPSS–28.0. Results: No grade III or IV hematological complications occurred. The overall response rate was 41% partial response, 27% stable and 32% progressive disease. Median overall survival (OS) was 38 months (95%CI 10.1–65.9). The OS was better in SQCC with 51 months The RegCTx specific survival was 13 months (95%CI 2.9–23.1) in the entire cohort and 25 months in SQCC patients. Conclusion: RegCTx is a valuable safe approach and superior to the current proposed therapeutic options in metastatic EC after failure to first-line therapy. |
| first_indexed | 2024-03-09T03:32:44Z |
| format | Article |
| id | doaj.art-b48668700ece40529ee7d21607faa286 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-09T03:32:44Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-b48668700ece40529ee7d21607faa2862023-12-03T14:53:06ZengMDPI AGCurrent Oncology1198-00521718-77292022-07-012974868487810.3390/curroncol29070386Regional Chemotherapy Is a Valuable Second-Line Approach in Metastatic Esophageal Cancer after Failure to First-Line Palliative TreatmentYogesh Vashist0Kornelia Aigner1Miriam Dam2Sabine Gailhofer3Karl R. Aigner4Clinic for Surgical Oncology, Medias Klinikum Burghausen, Krankenhausstrasse 3a, 84489 Burghausen, GermanyDepartment of Tumor Biology, Medias Klinikum Burghausen, Krankenhausstrasse 3a, 84489 Burghausen, GermanyClinic for Surgical Oncology, Medias Klinikum Burghausen, Krankenhausstrasse 3a, 84489 Burghausen, GermanyClinic for Surgical Oncology, Medias Klinikum Burghausen, Krankenhausstrasse 3a, 84489 Burghausen, GermanyClinic for Surgical Oncology, Medias Klinikum Burghausen, Krankenhausstrasse 3a, 84489 Burghausen, GermanyBackground: Therapeutic options in metastatic esophageal cancer (EC) are limited with unsatisfactory results. We evaluated the efficacy of regional chemotherapy (RegCTx) approach in diffuse metastatic EC using arterial infusion (AI), upper abdominal perfusion (UAP) and isolated-thoracic perfusion (ITP) in 14 patients (N = 8 adenocarcinoma (AC) and N = 6 squamous cell carcinoma (SQCC)) after failure to first-line palliative treatment. Methods: All patients had previously failed first-line palliative treatment attempt with systemic chemotherapy (sCTx). In total 51 RegCTx cycles (12 AI, 3 UAP and 36 ITP) were applied using cisplatin, Adriamycin and Mitomycin C. The outcome was evaluated using RECIST criteria with MediasStat 28.5.14 and SPSS–28.0. Results: No grade III or IV hematological complications occurred. The overall response rate was 41% partial response, 27% stable and 32% progressive disease. Median overall survival (OS) was 38 months (95%CI 10.1–65.9). The OS was better in SQCC with 51 months The RegCTx specific survival was 13 months (95%CI 2.9–23.1) in the entire cohort and 25 months in SQCC patients. Conclusion: RegCTx is a valuable safe approach and superior to the current proposed therapeutic options in metastatic EC after failure to first-line therapy.https://www.mdpi.com/1718-7729/29/7/386esophageal cancersurvivalsecond-line therapyregional chemotherapyisolated thoracic perfusionarterial infusion |
| spellingShingle | Yogesh Vashist Kornelia Aigner Miriam Dam Sabine Gailhofer Karl R. Aigner Regional Chemotherapy Is a Valuable Second-Line Approach in Metastatic Esophageal Cancer after Failure to First-Line Palliative Treatment Current Oncology esophageal cancer survival second-line therapy regional chemotherapy isolated thoracic perfusion arterial infusion |
| title | Regional Chemotherapy Is a Valuable Second-Line Approach in Metastatic Esophageal Cancer after Failure to First-Line Palliative Treatment |
| title_full | Regional Chemotherapy Is a Valuable Second-Line Approach in Metastatic Esophageal Cancer after Failure to First-Line Palliative Treatment |
| title_fullStr | Regional Chemotherapy Is a Valuable Second-Line Approach in Metastatic Esophageal Cancer after Failure to First-Line Palliative Treatment |
| title_full_unstemmed | Regional Chemotherapy Is a Valuable Second-Line Approach in Metastatic Esophageal Cancer after Failure to First-Line Palliative Treatment |
| title_short | Regional Chemotherapy Is a Valuable Second-Line Approach in Metastatic Esophageal Cancer after Failure to First-Line Palliative Treatment |
| title_sort | regional chemotherapy is a valuable second line approach in metastatic esophageal cancer after failure to first line palliative treatment |
| topic | esophageal cancer survival second-line therapy regional chemotherapy isolated thoracic perfusion arterial infusion |
| url | https://www.mdpi.com/1718-7729/29/7/386 |
| work_keys_str_mv | AT yogeshvashist regionalchemotherapyisavaluablesecondlineapproachinmetastaticesophagealcancerafterfailuretofirstlinepalliativetreatment AT korneliaaigner regionalchemotherapyisavaluablesecondlineapproachinmetastaticesophagealcancerafterfailuretofirstlinepalliativetreatment AT miriamdam regionalchemotherapyisavaluablesecondlineapproachinmetastaticesophagealcancerafterfailuretofirstlinepalliativetreatment AT sabinegailhofer regionalchemotherapyisavaluablesecondlineapproachinmetastaticesophagealcancerafterfailuretofirstlinepalliativetreatment AT karlraigner regionalchemotherapyisavaluablesecondlineapproachinmetastaticesophagealcancerafterfailuretofirstlinepalliativetreatment |